Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
Subject matters | Details | Categories |
---|---|---|
Health, Science and Technology
|
Incyte would like approval of a new drug to treat a rare form of cancer.
|
Regulation, Policies or Program
|
Address:
6500 Transcanada Hwy, Suite 400,
Pointe-Claire, QC H9R 0A5
Canada
Telephone number:
514-862-1662
Web address:
incyte.com
Ruth Pritchard, Director Stakeholder & Payer Engagement
Incyte Biosciences Canada Corporation is not a coalition.
The activities of Incyte Biosciences Canada Corporation are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Incyte Biosciences Canada Corporation does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Emily Kirk | No public offices held
Firm: CAPITAL HILL GROUP (THE)/LE GROUPE CAPITAL HILL